OverviewSuggest Edit

Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. The company aims to transform and simplify care for people with life-threatening illnesses. Its portfolio of products and pipeline of investigational drugs includes treatments for HIV/AIDS, liver diseases, cancer, inflammatory and respiratory diseases, and cardiovascular conditions. 
TypePublic
Founded1987
HQFoster City, US
Websitegilead.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Jan 2020)11,800(+8%)
Job Openings469
Revenue (FY, 2019)$22.4 B(+2%)
Share Price (Jul 2020)$76.4
Cybersecurity ratingCMore

Key People/Management at Gilead Sciences

Andrew Dickinson

Andrew Dickinson

Chief Financial Officer
Daniel O’Day

Daniel O’Day

Chairman and Chief Executive Officer
Johanna Mercier

Johanna Mercier

Chief Commercial Officer
Merdad Parsey

Merdad Parsey

Chief Medical Officer
Jyoti Mehra

Jyoti Mehra

Executive Vice President, Human Resources
William A. Lee

William A. Lee

Executive Vice President, Research
Show more

Gilead Sciences Office Locations

Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 14 other locations
Foster City, US (HQ)
333 Lakeside Dr
El Segundo, US
2355 Utah Ave
Emeryville, US
5858 Horton St #240
Miami, US
5200 Blue Lagoon Dr #450
Oceanside, US
4049 Avenida De La Plata
San Dimas, US
650 Cliffside Dr
Show all (18)

Gilead Sciences Financials and Metrics

Gilead Sciences Revenue

Embed Graph
View revenue for all periods
Gilead Sciences's revenue was reported to be $22.45 b in FY, 2019 which is a 1.5% increase from the previous period.
USD

Revenue (Q1, 2020)

5.5b

Gross profit (Q1, 2020)

4.6b

Gross profit margin (Q1, 2020), %

82.5%

Net income (Q1, 2020)

1.5b

EBIT (Q1, 2020)

2.4b

Market capitalization (3-Jul-2020)

95.8b

Closing stock price (3-Jul-2020)

76.4

Cash (31-Mar-2020)

10.1b

EV

109.8b
Gilead Sciences's current market capitalization is $95.8 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

26.1b22.1b22.4b

Revenue growth, %

(15%)1%

Cost of goods sold

4.4b4.9b4.7b

Gross profit

21.7b17.3b17.8b
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

6.5b7.1b6.5b5.1b5.6b5.6b5.3b5.7b5.6b5.5b

Cost of goods sold

957.0m1.1b1.0b1.0b1.2b1.1b957.0m1.0b1.0b969.0m

Gross profit

5.5b6.0b5.5b4.1b4.5b4.5b4.3b4.7b4.6b4.6b

Gross profit Margin, %

85%84%84%80%79%81%82%82%82%83%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

7.6b17.9b11.6b

Accounts Receivable

3.9b3.3b3.6b

Prepaid Expenses

1.7b1.6b1.4b

Inventories

801.0m814.0m922.0m
Quarterly
USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

10.3b8.7b11.5b7.6b13.2b14.6b16.9b11.2b9.5b10.1b

Accounts Receivable

4.0b4.5b4.1b3.8b3.5b3.5b3.3b3.4b3.3b3.9b

Prepaid Expenses

1.8b1.6b1.7b1.6b2.4b2.2b1.9b2.3b1.3b1.3b

Inventories

1.5b1.4b1.1b885.0m859.0m816.0m898.0m884.0m882.0m986.0m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

4.6b5.5b5.4b

Depreciation and Amortization

1.3b1.4b1.4b

Inventories

(253.0m)(310.0m)(95.0m)

Accounts Payable

(430.0m)(39.0m)(61.0m)
USDQ1, 2017

Revenue/Employee

722.8k

Debt/Equity

1.3 x

Debt/Assets

0.5 x

Financial Leverage

2.8 x
Show all financial metrics

Gilead Sciences Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Countries

30 35 35 35

Products

25 27 24 24
Show all operating metrics

Gilead Sciences Acquisitions / Subsidiaries

Company NameDateDeal Size
Forty SevenMarch 21, 2020$4.90 b
Cell Design LabsDecember 07, 2017$567 m
Kite PharmaAugust 28, 2017$11.90 b
Nimbus ApolloMay 17, 2016
EpitherapeuticsMay 06, 2015$65 m
Phenex PharmaceuticalsJanuary 06, 2015$470 m
YM BioSciencesFebruary 08, 2013$487.60 m
PharmassetNovember 21, 2011$11 b
Calistoga PharmaceuticalsMarch 01, 2011$375 m
Arresto BioSciencesDecember 20, 2010
Show more

Gilead Sciences Cybersecurity Score

Cybersecurity ratingPremium dataset

C

70/100

SecurityScorecard logo

Gilead Sciences Revenue Breakdown

Embed Graph

Gilead Sciences revenue breakdown by business segment: 98.5% from Product Sales and 1.5% from Other

Gilead Sciences revenue breakdown by geographic segment: 17.0% from Europe, 74.1% from United States and 8.9% from Other

Gilead Sciences Online and Social Media Presence

Embed Graph

Gilead Sciences News and Updates

Thinking about buying stock in Gilead Sciences, Boeing, Boxlight Corp, Worthington Industries, or Raven Industries?

NEW YORK, June 29, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GILD, BA, BOXL, WOR, and RAVN. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Gilead Sciences to study use of coronavirus drug in children

Gilead Sciences Inc. said Wednesday it started a clinical trial of using its drug remdesivir to treat COVID-19 in pediatric patients. "While the novel coronavirus appears to disproportionally affect adults - especially the elderly and those with underlying health conditions - concerning reports hav…

Dr Reddy’s Inks Pact With Gilead Sciences For Remdesivir

Dr. Reddys will receive technology transfer from Gilead for manufacturing of this drug.

Thinking about buying stock in TOP Ships, Gilead Sciences, Seanergy Maritime, Denbury Resources, or Noble Corp?

NEW YORK, June 8, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TOPS, GILD, SHIP, DNR, and NE. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Current Market Scenario of Global Compensated Cirrhosis Type C Market| Gilead Sciences, Inc., Cadila Healthcare Ltd, Intercept Pharmaceuticals, Inc.

This report also researches and evaluates the impact of Covid-19 outbreak on the Compensated Cirrhosis Type C industry, involving potential opportunity and challenges, drivers and risks. We present the impact assessment of Covid-19 effects on Compensated Cirrhosis Type C and market growth forecast b…

Gilead Sciences shares halted in premarket for pending news

Gilead Sciences shares halted in premarket for pending news
Show more

Gilead Sciences Frequently Asked Questions

  • When was Gilead Sciences founded?

    Gilead Sciences was founded in 1987.

  • Who are Gilead Sciences key executives?

    Gilead Sciences's key executives are Andrew Dickinson, Daniel O’Day and Johanna Mercier.

  • How many employees does Gilead Sciences have?

    Gilead Sciences has 11,800 employees.

  • What is Gilead Sciences revenue?

    Latest Gilead Sciences annual revenue is $22.4 b.

  • What is Gilead Sciences revenue per employee?

    Latest Gilead Sciences revenue per employee is $1.9 m.

  • Who are Gilead Sciences competitors?

    Competitors of Gilead Sciences include Novo Nordisk, Celgene and Amgen.

  • Where is Gilead Sciences headquarters?

    Gilead Sciences headquarters is located at 333 Lakeside Dr, Foster City.

  • Where are Gilead Sciences offices?

    Gilead Sciences has offices in Foster City, El Segundo, Emeryville, Miami and in 14 other locations.

  • How many offices does Gilead Sciences have?

    Gilead Sciences has 18 offices.